Latest News

An FDA advisory committee found that an OTC decongestant, phenylephrine, works no better than a placebo at relieving congestion. Yale researchers discuss how drugs with insufficient evidence make it to market.

The Yale Open Data Access (YODA) Project, a pioneering initiative to promote open science and facilitate sharing of clinical trial research data, has reached the milestone of supporting more than 100 publications.

The Yale-Mayo Clinic FDA Center of Excellence in Regulatory Science and Innovation (CERSI) was recently renewed with an award of up to $50M for five years from the U.S. Food and Drug Administration (FDA). The partnership between Yale School of Medicine (YSM) and Mayo Clinic provides academic scientists the opportunity to perform regulatory science research, training, and education in collaboration with the FDA.

Reshma Ramachandran, MD, MPP, MHS, named by Endpoint News, the leading pharm/biotech trade news organization, as one of the 20 under 40 "next generation" of biotech leaders!

Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine...

Reshma Ramachandran, MD, MPP, MHS, not only believes in equitable access to healthcare and medical products but is a formidable force in advocating for it.

Changes were expected to get folded into renewal of the Prescription Drug User Fee Act in September, but Congress passed it without any riders. That worried Dr. Reshma Ramachandran, of Yale School of Medicine, who was one of the doctors who traveled to Washington, D.C., to talk to legislators about accelerated approval updates.

Jennifer Miller, PhD, associate professor of medicine (general medicine), specializes in developing and using metrics to enhance accountability and social responsibility in biomedical innovation.

Reshma Ramachandran, MD, MPP, MHS, assistant professor of medicine (general medicine), talks about the new law that allows the FDA to require companies to start confirmatory studies before it grants accelerated approval.